Fujirebio Receives FDA Clearance for First Blood-Based Test to Aid Alzheimer’s Diagnosis in the U.S.

Fujirebio announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/&beta...

May 19, 2025 | Monday | News
Shanghai Ark Biopharma Reports Positive Phase II Results for AK3280 in IPF Patients Signaling New Hope in Fibrotic Lung Disease Treatment

Shanghai Ark Biopharmaceutical announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of idiopathic...

May 16, 2025 | Friday | News
GeneFab and RegCell Unite to Accelerate U.S. Clinical Manufacturing of Next-Gen Treg Therapies

GeneFab, a next-generation cell and gene therapy-focused contract research, development, and manufacturing organization (CRDMO), has partnered with RegCe...

May 08, 2025 | Thursday | News
CEO Chris Cargill Marks One-Year Transformation Milestone as Nxera Pharma Reports Strong Q1 2025 Progress

Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated resu...

May 05, 2025 | Monday | Company results
PCI Pharma Services Acquires Ajinomoto Althea to Expand Global Sterile Fill-Finish and ADC Capabilities

Along with PCI’s own robust infrastructure expansions, acquisition furthers CDMO’s recent growth in sterile fill-finish, advanced drug delivery...

May 02, 2025 | Friday | News
Cordis Unveils Groundbreaking Long-Term Data Supporting SELUTION SLR™ DEB in Treating Complex PAD

 Cordis, a global leader in interventional cardiovascular and endovascular technologies, announced new data from two major peripheral studies evaluati...

April 25, 2025 | Friday | News
Daiichi Sankyo and AstraZeneca’s ENHERTU Combo Outperforms Standard of Care in First-Line HER2+ Metastatic Breast Cancer

DESTINY-Breast09 phase 3 trial of Daiichi Sankyo and AstraZeneca’s ENHERTU is the first trial in more than a decade to demonstrate superior eff...

April 21, 2025 | Monday | News
Henlius Hosts World R&D Day 2025, Showcasing Innovation and Global Collaboration Under "Collaborate to Create" Theme

 Henlius  celebrated its World R&D Day 2025, under the theme "Collaborate to Create", bringing together senior executives, experts and indust...

April 21, 2025 | Monday | News
CSL Behring Launches ANDEMBRY in Japan for Hereditary Angioedema Prevention

CSL Behring K.K.  President and Representative Director: Izumi Yoshida)  announced that it launched ANDEMBRY® Subcutaneous Injection 200 mg P...

April 21, 2025 | Monday | News
Zynext Ventures Invests in Feldan Therapeutics to Advance Next-Gen Intracellular Drug Delivery

Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), announced its investment in Feldan Therapeutics...

April 17, 2025 | Thursday | News
Nikon CeLL and RoosterBio Ink Licensing Deal to Advance Stem Cell and EV Therapies in Japan

Nikon CeLL innovation Co., Ltd. (NCLi), a subsidiary of Nikon Corporation has entered into a strategic licensing agreement with RoosterBio, Inc. (RoosterBi...

April 16, 2025 | Wednesday | News
Lecanemab Becomes First Approved Disease-Modifying Therapy for Early Alzheimer’s in the EU

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild de...

April 16, 2025 | Wednesday | News
Regeneron and Sanofi Receive Approval for Dupixent® in Japan to Treat Chronic Obstructive Pulmonary Disease (COPD)

TARRYTOWN -- Regeneron Pharmaceuticals, and Sanofi announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan ...

March 31, 2025 | Monday | News
Rhythm Pharmaceuticals Receives Orphan Drug Designation for Setmelanotide in Japan for Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc., a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendoc...

March 21, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close